ENA0000GenomicsLaboratory of molecullar oncology, National Cancer Institutehttps://www.ebi.ac.uk/ena/browser/view/PRJNA400452Homo sapiensThe clinical significance of conventional treatment is based on an accumulated dose and usually consists of single daily irradiations of 1.8 - 2 Gy fractions. The most important molecule mediating DNA damage response (DDR) is the transcription factor p53. When activated, p53 mediates processes which are important for the cellular response to the clinical irradiation. These processes can be altered in cells having non-functional p53 that decrease cancer cell sensitivity to the fractionated irradiation. Therefore, the ongoing investigation of genomic scale expression changes in colorectal cancer cell line HCT116 with non-functional gene p53 following single and multiple fractions of irradiation provide researchers with essential data studying and incorporating novel therapies in the cancer treatment. Overall design: RNA was harvested from colorectal cancer cell line HCT116_p53minus 4h after the treatment of single (2 Gy) or fractionated (5x2 Gy) ionizing radiation dose. Non-treated cells were used as a control.ENAcarcinoma of large bowel, advanced, d230, malignant tumour of large bowel, HCT116, Gene, carcinoma of colorectum, dTAFII250, malignant large bowel neoplasm, EfW1, autosomal dominant, dmTAF[[II]]230, colorectal cancer, dmTAF1, Taf230, malignant large intestine tumor, colorectum cancer, malignant neoplasm of the large intestine, TAF250, Taf200, malignant large intestine tumour, dTAF[[II]]250, Gene Expressions, TFIID TAF250, cel, cell, large bowel carcinoma, malignant tumour of the large intestine, malignant colorectal tumor, Taf1p, Expressions, large intestine cancer, cancer of the large intestine, dTAF250, malignant colorectal neoplasm, Radiations., Expression, carcinoma of the large bowel, carcinoma of large intestine, TAF, somatic mutation, colorectal (colon or rectal) cancer, malignant tumor of the large bowel, malignant tumor of large intestine, dTAF[[II]]230, TAF[[II]]250, malignant large bowel tumor, TAF200, carcinoma of the large intestine, malignant neoplasm of large bowel, l(3)84Ab, BG:DS00004.13, large intestine carcinoma, TAFII-250, somatic, TAF250/230, malignant large intestine neoplasm, Cell, dTAF230, HCT116 cell, TAFII250, malignant neoplasm of large intestine, p230, cancer of colorectum, TAF[[II]]250/230, TFIID, CRC, large bowel cancer, Taf[[II]]250, colorectal cancer with chromosomal instability, malignant tumor of large bowel, TAF[[II]]230, HCT-116, susceptibility to, colorectum carcinoma, malignant colorectum neoplasm, TAF[II]250, CG17603, TAF[[II]], cancer of large bowel, malignant neoplasm of the large bowel, colon cancer, DmelCG17603, malignant colorectal tumour, Taf250, colorectal carcinoma, HCT 116, SR3-5, malignant neoplasm of colorectum, malignant tumour of the large bowel, malignant tumour of large intestine, cancer of the large bowel, malignant tumor of the large intestine, HCT-116 cell, cancer of large intestine, malignant large bowel tumour, TAF230, TAF1human being, human., man0.00.00.00.00.00falseHomo sapiensGene expression profile of colorectal cancer HCT116_p53minus cells treated with single (2Gy) or fractionated (5 x 2Gy) doses of ionizing radiation.2022-05-122017-08-30PRJNA400452GSE1031799606